Eledon Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
David-Alexandre C Gros, Chief Executive Officer and a Director of Eledon Pharmaceuticals, Inc., reported multiple transactions in common stock on July 31, 2026.
NASDAQ
Steven Perrin, President and a Director of Eledon Pharmaceuticals, Inc., reported multiple transactions in common stock on July 31, 2026.
NASDAQ
Eledon Pharmaceuticals Director John S. McBride acquired 3,430 shares of common stock through the settlement of restricted stock units.
NASDAQ
Eledon Pharmaceuticals Director Jan Hillson acquired 3,430 shares of common stock through the settlement of vested restricted stock units.
NASDAQ
Eledon Pharmaceuticals Director Allan Kirk converted 3,430 restricted stock units into common stock on January 10, 2026, increasing his direct beneficial ownership.
NASDAQ
Eledon Pharmaceuticals Director Keith Katkin converted 8,575 restricted stock units into common stock on January 10, 2026.
NASDAQ
Eledon Pharmaceuticals Director June Lee acquired 3,430 shares of common stock through the settlement of restricted stock units.
NASDAQ
Eledon Pharmaceuticals Director James A. Robinson Jr. acquired 3,430 shares of common stock through the settlement of restricted stock units.
NASDAQ
Form 4: Eledon Pharmaceuticals Director Jan Hillson Acquires Stock Options and Restricted Stock Units
Director Jan Hillson of Eledon Pharmaceuticals acquired stock options for 30,870 shares and 3,430 restricted stock units on January 10, 2025.
NASDAQ
Eledon Pharmaceuticals director John S. McBride was granted stock options and restricted stock units on January 10, 2025.
NASDAQ
Eledon Pharmaceuticals' CEO, David-Alexandre C. Gros, was granted stock options and restricted stock units as part of his compensation package.
NASDAQ
Eledon Pharmaceuticals' Chief Financial Officer, Paul Sean Little, was granted stock options and restricted stock units on January 10, 2025, according to a recent SEC filing.
NASDAQ
Form 4: Eledon Pharmaceuticals Director Keith Katkin Acquires Stock Options and Restricted Stock Units
Eledon Pharmaceuticals director Keith Katkin was granted stock options for 77,175 shares and 8,575 restricted stock units on January 10, 2025.
NASDAQ
Eledon Pharmaceuticals' President, Steven Perrin, was granted stock options for 243,000 shares and 27,000 restricted stock units on January 10, 2025.
NASDAQ
Bryan E. Smith, General Counsel and Corporate Secretary of Eledon Pharmaceuticals, was granted stock options and restricted stock units on January 10, 2025.
NASDAQ
Eledon Pharmaceuticals director June Lee was granted stock options for 30,870 shares and 3,430 restricted stock units on January 10, 2025.
NASDAQ
Eledon Pharmaceuticals director James A. Robinson Jr. was granted stock options and restricted stock units, according to a recent SEC filing.
NASDAQ
Form 4: Eledon Pharmaceuticals Director Allan Kirk Acquires Stock Options and Restricted Stock Units
Director Allan Kirk of Eledon Pharmaceuticals acquired stock options for 30,870 shares and 3,430 restricted stock units on January 10, 2025.
NASDAQ
Eledon Pharmaceuticals' Chief Financial Officer, Paul Little, acquired 525,032 shares of common stock through the vesting of a stock option.
NASDAQ
Eledon Pharmaceuticals President, Steven Perrin, acquired 840,438 shares of common stock through the vesting of a stock option.
NASDAQ
Eledon Pharmaceuticals' General Counsel, Bryan Smith, exercised stock options for 474,350 shares after performance conditions were met.
NASDAQ
Eledon Pharmaceuticals CEO, David-Alexandre C. Gros, exercised stock options for 1,015,743 shares after meeting performance-based vesting criteria.
NASDAQ
BVF Partners and affiliated entities report transactions involving common stock, pre-funded warrants, convertible preferred stock, and warrants of Eledon Pharmaceuticals, Inc.
NASDAQ
Eledon Pharmaceuticals' CEO, David-Alexandre C. Gros, acquired 517,454 shares of common stock through the vesting of a stock option on June 13, 2024.
NASDAQ
Paul Sean Little, CFO of Eledon Pharmaceuticals, acquired stock options for 267,470 shares after meeting performance-based vesting criteria.
NASDAQ
Steven Perrin, President of Eledon Pharmaceuticals, acquired 428,148 shares of common stock through the vesting of a stock option on June 13, 2024.
NASDAQ
Bryan E. Smith, General Counsel and Corporate Secretary of Eledon Pharmaceuticals, acquired 241,650 shares of common stock through the vesting of a stock option on June 13, 2024.
NASDAQ
BVF Partners and affiliated entities report the acquisition of common stock and pre-funded warrants in Eledon Pharmaceuticals through a private placement.